Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaltox: Reduced Cyclosporine A in Pediatric Kidney Transplant
NCT00663455Phase 4Terminated
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Dec 2008
- Primary completion
- Dec 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine in kidney transplant rejection (2 arms), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Mean decline per month in glomerular filtration rate at 24 months. Started Dec 2008; status: terminated.
02
Drugs
cyclosporine
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00663455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663455.